Status:
COMPLETED
Arterial Function and Atherosclerosis in Essential Thrombocythemia
Lead Sponsor:
University Medical Centre Ljubljana
Conditions:
Atherosclerosis
Eligibility:
All Genders
18+ years
Brief Summary
The aim of the study is to examine (a) whether patients with JAK2 V617F positive ET in comparison to age-and sex-matched, apparently healthy control subjects show more advanced progression of arterial...
Detailed Description
1. Patients and control subjects Patients are selected from the database of the Department of Haematology at University Medical Centre Ljubljana, Slovenia, who were diagnosed with JAK2 V617F posit...
Eligibility Criteria
Inclusion
- patients with JAK2 V617F positive essential thrombocythemia
- age-and sex-matched apparently healthy control subjects
Exclusion
- personal history of any atherosclerotic vascular disease (myocardial infarction, angina pectoris, peripheral arterial disease, aortic disease, transient ischemic attack or ischemic stroke)
- chronic kidney disease stage 3 and above
- known cancer
- chronic inflammatory disease
- autoimmune disease
- pregnancy
Key Trial Info
Start Date :
January 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 5 2021
Estimated Enrollment :
82 Patients enrolled
Trial Details
Trial ID
NCT03828422
Start Date
January 1 2014
End Date
August 5 2021
Last Update
November 4 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.